Literature DB >> 17706778

Vaccination against the feline immunodeficiency virus: the road not taken.

Sylvie Lecollinet1, Jennifer Richardson.   

Abstract

Natural infection of domestic cats by the feline immunodeficiency virus (FIV) causes acquired immunodeficiency syndrome (AIDS). FIV is genetically related to human immunodeficiency virus (HIV), and the clinical and biological features of infections caused by feline and human viruses in their respective hosts are highly analogous. Although the obstacles to vaccinating against FIV and HIV would seem to be of comparable difficulty, a licensed vaccine against feline AIDS is already in widespread use in several countries. While this seemingly major advance in prevention of AIDS would appear to be highly instructive for HIV vaccine development, its message has not been heeded by investigators in the HIV field. This review endeavours to relate what has been learned about vaccination against feline AIDS, and to suggest what this may mean for HIV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706778     DOI: 10.1016/j.cimid.2007.07.007

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  10 in total

Review 1.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

2.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

3.  Molecular characterization of feline immunodeficiency virus budding.

Authors:  Benjamin G Luttge; Miranda Shehu-Xhilaga; Dimiter G Demirov; Catherine S Adamson; Ferri Soheilian; Kunio Nagashima; Andrew G Stephen; Robert J Fisher; Eric O Freed
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

4.  Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.

Authors:  Saipiroon Maksaereekul; Robert A Dubie; Xiaoying Shen; Hung Kieu; Gregg A Dean; Ellen E Sparger
Journal:  Vaccine       Date:  2009-04-17       Impact factor: 3.641

Review 5.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

Review 6.  Applications of the FIV Model to Study HIV Pathogenesis.

Authors:  Craig Miller; Zaid Abdo; Aaron Ericsson; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

Review 7.  Important mammalian veterinary viral immunodiseases and their control.

Authors:  J R Patel; J G M Heldens; T Bakonyi; M Rusvai
Journal:  Vaccine       Date:  2012-01-17       Impact factor: 3.641

8.  Serum Samples from Co-Infected and Domestic Cat Field Isolates Nonspecifically Bind FIV and Other Antigens in Enzyme-Linked Immunosorbent Assays.

Authors:  Alex Moskaluk; Mary Nehring; Sue VandeWoude
Journal:  Pathogens       Date:  2021-05-28

Review 9.  Virus-host interaction in feline immunodeficiency virus (FIV) infection.

Authors:  Sueli Akemi Taniwaki; Andreza Soriano Figueiredo; João Pessoa Araujo
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2013-08-02       Impact factor: 2.268

10.  Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV).

Authors:  Mark Westman; Dennis Yang; Jennifer Green; Jacqueline Norris; Richard Malik; Yasmin A Parr; Mike McDonald; Margaret J Hosie; Sue VandeWoude; Craig Miller
Journal:  Viruses       Date:  2021-03-12       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.